Free Submission Public Relations &
Deutsch English


"Mexico Pharmaceuticals & Healthcare Report Q1 2014" Published

Print article Print article
2013-12-02 14:06:32 - New Healthcare research report from Business Monitor International is now available from Fast Market Research

Mexico's encouraging macroeconomic growth prospects, business-friendly environment and improving pharmaceutical regulatory regime have made it an increasingly attractive market to multinationals. Apart from the ageing population and the increasing incidence of chronic diseases, the government's commitment to improve its healthcare services is another fundamental factor driving market growth. In addition, its unparalleled policies in market accessibility have made Mexico an important hub for multinationals to enter other Latin American countries.

Headline Expenditure Projections

* Pharmaceuticals: MXN176.00bn (US$13.38bn) in 2012 to MXN191.71bn (US$15.10bn) in 2013; +8.9% in local currency terms and +12.8% in US dollar terms. Forecast increased from Q413 due to positive industry developments.
* Healthcare: MXN961.30bn (US$73.09bn) in 2012 to MXN1,046.29bn (US$82.39bn) in 2013; +8.8% in local currency terms and

+12.7% in US dollar terms. Forecast increased from Q413 due to changes in macroeconomic forecasts.

Full Report Details at
- ..

Risk/Reward Rating: Mexico scores 60.6 in BMI's Pharmaceutical and Healthcare Risk/Reward Rating (RRR), making it the fifth-most attractive pharmaceutical market in America. We have reweighted the RRR components this quarter to improve the tool and adjusted scores for all markets in our Pharmaceuticals & Healthcare reports.

Key Trends And Developments

* In September 2013, Mexican President Enrique Pena Nieto unveiled the fiscal reform proposal to bolster government revenue. We highlight the exemption of medicines to VAT and the creation of universal social security will further improve the long-term outlook of the country's pharmaceutical market..
* In August 2013, UN Comtrade reported that medicine imports in Mexico reached US$4.6bn in 2012.
* In August 2013, Cofepris started a consultancy service to discourage self-medication and unfair competition, according to the commissioner of Cofepris, Mikel Arriola. As part of the programme, Cofepris will open 10,000 clinics at pharmacies in the country, which will provide about 250,000 daily consultations to people who are not able to attend other medical care centres.
. * In July 2013, Mexican pharmaceutical company Genomma Lab reported that sales increased 22.1% year-on-year to MXN2.53bn (US$200.39mn) in Q213 (ended June 2013).
* In July 2013, Novo Nordisk announced that its new basal insulin (degludec) designed for the treatment of Type I and Type II diabetes is commercially available in Mexico

BMI Economic View: In our previous update we adjusted down our real GDP growth forecast for 2013, from 3.6% to a below-consensus 3.0%, and the release of Q113 GDP by expenditure confirms this more pessimistic outlook. Moreover, we highlight that the risks to our view lie weighted firmly to the downside, with potential for an uptick in imported inflation to hamper private consumption and indications that an uncertain global economic environment may weigh on investment to a greater extent than we are currently envisioning..

BMI Political View: While the election authority has ordered a recount, preliminary results suggest that the centre-right Partido Accion Nacional has won the gubernatorial race in Baja California. If these results hold, it will help maintain the tripartite Pact for Mexico and keep President Enrique Pena Nieto's reform agenda on course. On a less positive note, we believe the heightened local violence seen during the election is only likely to continue as Mexico's drug cartels continue to fracture..

Partial Table of Contents:

BMI Industry View
- Political
- Economic
- Business Environment
Industry Forecast
- Pharmaceutical Market Forecast
- Table: Pharmaceutical Sales Indicators, 2009-2017
- Healthcare Market Forecast
- Table: Healthcare Expenditure Indicators, 2009-2017
- Table: Healthcare Governmental Indicators 2009-2017
- Table: Healthcare Private Indicators 2009-2017
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators, 2009-2017
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators, 2009-2017
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators, 2009-2017
- OTC Drug Market Forecast
- Table: OTC Medicine Sales Indicators, 2009-2017
- Pharmaceutical Trade Forecast
- Table: Mexico Pharmaceutical Trade Data And Forecasts (US$mn), 2009-2017
- Other Healthcare Data Forecasts
- Key Risks To BMI's Forecast Scenario
Macroeconomic Forecasts
- Economic Activity
- Table: Mexico - Gdp By Expenditure, Real Growth %
Industry Risk Reward Ratings
- Americas Risk/Reward Ratings
- Industry Risk/Reward Ratings
- Rewards
- Risks
Market Overview
Industry Trends And Developments
- Epidemiology
- Healthcare Sector
- Health Insurance
- Healthcare Sector Funding
- Medical Tourism
- Research & Development
- Clinical Trials
- Table: Clinical Trial Regulation In Mexico
Regulatory Development
- Regulatory Development
- Biologics And Biosimilar Guidelines
- Intellectual Property Issues
- Intellectual Property Challenges
- Table: Mexican Marketing Applications In Alleged Violation Of Patent Rights
- Counterfeit Drugs
- Pricing & Reimbursement
- Reimbursement
- Pricing Issues
- Pricing Developments
- Reimbursement Issues
- Other Regulatory Developments
Competitive Landscape
- Pharmaceutical Sector
- Domestic Industry
- Table: AstraZeneca Sales, 2005-10
- Pharmaceutical Distribution
- Pharmaceutical Retail Sector
- Table: IMSS Financial Indicators, 2000-11 (MXNmn)
- Table: SPSS Budget, 2004-11 (MXNmn)
- Other Developments
Company Profile
- Genomma Labs
- Pfizer
- GlaxoSmithKline (GSK)
- Sanofi

Full Table of Contents is available at:

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Bill Thompson
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact | BidVertiser